Among these immune checkpoints, therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1) has been rapidly developing as oncotherapy for various carcinomas, including pancreatic cancer. The gene discussed is CD274; the disease is pancreatic neoplasm.